2. Maeda K. New method of measurement of epidermal turnover in humans. Cosmetics. 2017;4:47.

3. Maeda K. Timeline of the development of skin-lightening active ingredients in Japan. Molecules. 2022;27:4774.

4. Abiko Y., Iwamoto M. Plasminogen-plasmin system: VII. Potentiation of antifibrinolytic action of a synthetic inhibitor, tranexamic acid, by α2-macroglobulin antiplasmin. Biochim Biophys Acta. 1970;214:411–18.

5. Japanese Pharmacopoeia and Related Informations. The Japanese Pharmacopoeia 18th Edition, Tranexamic Acid. 1850–51.

6. Dai L., Bevan D., Rangarajan S., Sшrensen B., Mitchell M. Stabilization of fibrin clots by activated prothrombin complex concentrate and tranexamic acid in FVIII inhibitor plasma. Haemophilia. 2011;17:e944–48. doi: 10.1111/j.1365-2516.2011.02491.x.

7. Zhang X.Y., Yang X.H., Yang H., Yang Y.P. Study of inhibitory effect of acidum tranexamicum on melanin synthesis. Chin J Dermatovenerol Int Tradit West Med. 2003;2:227–29.

8. Kim M.S., Bang S.H., Kim J.H., et al. Tranexamic acid diminishes laser-induced melanogenesis. Ann Dermatol. 2015;27:250–56. doi: 10.5021/ad.2015.27.3.250.

9. Lindgren A.L., Austin A.H., Welsh K.M. The Use of Tranexamic acid to prevent and treat post-inflammatory hyperpigmentation. J Drugs Dermatol. 2021;20:344–45. doi: 10.36849/JDD.5622.

10. Grimes P.E. Managment of hyperpigmentation in darker racial ethnic groups. Semin Cutan Med Surg. 2009;28:77–85. doi: 10.1016/j.sder.2009.04.001.

11. Tomita Y., Maeda K., Tagami H. Melanocyte-stimulating properties of arachidonic acid metabolites: possible role in postinflammatory pigmentation. Pigment Cell Res. 1992;5:357–61. doi: 10.1111/j.1600-0749.1992.tb00562.x.

12. Ortonne J. Retinoic acid and pigment cells: a review of in-vitro and in-vivo studies. Br J Dermatol. 1992;127(Suppl 41):43–7. doi: 10.1111/j.1365-2133.1992.tb16987.x.

13. Chang M.W. Disorders of hyperpigmentation. In: Bolognia J.L., Jorizzo J.L., Rapini R.P., editors. Dermatology. 2nd ed. Elsevier Mosby, 2009. P. 333–89.

14. Taylor S.C., Grimes P.E., Lim J., et al. Postinflammatory Hyperpigmentation. J Cutan Med Surg. 2009;13:183–91. doi: 10.2310/7750.2009.08077

15. Nordlund J.J., Abdel-Malek Z.A. Mechanisms for post-inflammatory hyperpigmentation and hypopigmentation. In: Bagnara J.T., editor. Advances in Pigment Cell Research: Proceedings of Symposia and Lectures from the Thirteenth International Pigment Cell Conference. New York, NY: Liss; 1988. P. 219–39. Tucson, AZ; October 5–9 1986.

16. Masu S., Seiji M. Pigmentary incontinence in fixed drug eruptions. Histologic and electron microscopic findings. J Am Acad Dermatol. 1983;8:525–32. doi: 10.1016/s0190-9622(83)70060-5.

17. Chang W.C., Shi G.Y., Chow Y.H., et al. Human plasmin induces a receptor-mediated arachidonate release coupled with G proteins in endothelial cells. Am J Physiol. 1993;264:C271–81. doi: 10.1152/ajpcell.1993.264.2.C271.

18. Ishihara Y., Kitamura S., Kosaka K., Harasawa M. Tranexamic acid no prostaglandin gouseisogai ni kansuru kenkyu. Jpn Pharmacol Ther. 1978;6:398–402. (In Japanese).

19. Weide I., Tippler B., Syrovets T., Simmet T. Plasmin is a specific stimulus of the 5-lipoxygenase pathway of human peripheral monocytes. Thromb Haemost. 1996;76:561–68.

20. Sasaki H., Akamatsu H., Matoba Y., et al. Effects of Tranexamic Acid on Neutrophil Chemotaxis, Phagocytosis and Reactive Oxygen Species Generation in vitro. Jpn Pharmacol Ther. 1994;22:1429–35. (In Japanese).

21. Toki N., Takasugi S., Fujii K. Basic research of histaminergic drugs and antihistaminergic drugs. Med. Consult. New Remedies.1981;18:1195–202. (In Japanese).

22. Xing X., Xu Z., Chen L., et al. Tranexamic acid inhibits melanogenesis partially via stimulation of TGF-β1 expression in human epidermal keratinocytes. Exp. Dermatol. 2022;31:633–40. doi: 10.1111/exd.14509.

23. Zhu J.W., Ni Y.J., Tong X.Y., et al. Tranexamic acid inhibits angiogenesis and melanogenesis in vitro by targeting VEGF receptors. Int J Med Sci. 2020;17:903–11. doi: 10.7150/ijms.44188.

24. Tomita Y., Maeda K., Tagami H. Mechanisms for hyperpigmentation in postinflammatory pigmentation, ulticaria pigmentosa and sunburn. Dermatologica. 1989;179:49–53. doi: 10.1159/000248449.

25. Nordlund J.J., Collins C.E., Rheins L.A. Prostaglandin E2 and D2 but not MSH stimulate the proliferation of pigment cells in the pinnal epidermis of the DBA/2 mouse. J Invest Dermatol. 1986;86:433–37. doi: 10.1111/1523-1747.ep12285717.

26. Tomita Y., Maeda K., Tagami, H. Melanocyte-stimulating properties of arachidonic acid metabolites: Possible role in postinflammatory pigmentation. Pigment Cell Res. 1992;5:357–61. doi: 10.1111/j.1600-0749.1992.tb00562.x.

27. Maeda K., Naganuma, M. Melanocyte-stimulating properties of secretory phospholipase A2. Photochem Photobiol. 1997;65:145–49. doi: 10.1111/j.1751-1097.1997.tb01890.x.

28. Tomita Y., Maeda K., Tagami, H. Leukotrienes and thromboxane B2 stimulate normal human melanocytes in vitro: Possible inducers of postinflammatory pigmentation. Tohoku J Exp Med. 1988;156:303–4. doi: 10.1620/tjem.156.303.

29. Morelli J.G., Hake S.S., Murphy R.C., Norris D.A. Leukotriene B4-induced human melanocyte pigmentation and leukotriene C4-induced human melanocyte growth are inhibited by different isoquinolinesulfonamides. J Invest Dermatol. 1992;98:55–8. doi: 10.1111/1523-1747.ep12494602.

30. Maeda K., Naganuma M. Topical trans-4-aminomethylcyclohexanecarboxylic acid prevents ultraviolet radiation-induced pigmentation. J Photochem Photobiol B Biol. 1998;47:136–41. doi: 10.1016/s1011-1344(98)00212-7.

31. Nakano T., Fujita H., Kikuchi N., Arita H. Plasmin converts pro-form of group I phospholipase A2 into receptor binding, active forms. Biochem Biophys Res Commun. 1994;198:10–5. doi: 10.1006/bbrc.1994.1002.

32. Maeda K. Tranexamic acid. Mon. Book Derma. 2005;98:35–42. (In Japanese).

33. Maeda K., Tomita Y. Mechanism of the inhibitory effect of tranexamic acid on melanogenesis in cultured human melanocytes in the presence of keratinocyte-conditioned medium. J. Health Sci. 2007;53:389–96.

34. Takada A., Takada Y. Inhibition by tranexamic acid of the conversion of single-chain tissue plasminogen activator to its two chain form by plasmin: The presence on tissue plasminogen activator of a site to bind with lysine binding sites of plasmin. Thromb Res.1989;55:717–25. doi: 10.1016/0049-3848(89)90302-2.

35. Miles L.A., Dahlberg C.M., Plescia J., et al. Role of cell-surface lysines in plasminogen binding to cells: Identification of alpha-enolase as a candidate plasminogen receptor. Biochemistry. 1991;30:1682–91.

36. Plow E.F., Herren T., Redlitz A., et al. The cell biology of the plasminogen system. FASEB J. 1995;9:939–455. doi: 10.1096/fasebj.9.10.7615163.

37. Bizik J., Stephens R.W., Grofova M., Vaheri A. Binding of tissue-type plasminogen activator to human melanoma cells. J Cell Biochem. 1993;51:326–35. doi: 10.1002/jcb.240510312.

38. Isseroff R.R., Rifkin D.B. Plasminogen is present in the basal layer of the epidermis. J Invest Dermatol. 1983;80:297–99. doi: 10.1111/1523-1747.ep12534677.

39. Spiers E.M., Lazarus G.S., Lyons-Giordano B. Expression of plasminogen activators in psoriatic epidermis. J Invest Dermatol. 1994;102:333–38. doi: 10.1111/1523-1747.ep12371792.

40. Loud L.R., Eriksen J., Ralfkiaer E., Romer J. Differential expression of urokinase plasminogen activator, its receptor, and inhibitors in mouse skin after exposure to a tumor-promoting phorbol ester. J Invest Dermatol. 1996;106:622–30. doi: 10.1111/1523-1747.ep12345425.

41. Ichikawa K., Takashima A., Yasuda S., Mizuno N. Enhanced rabbit skin plasmin activity by UV irradiation. Dermatologica. 1989;179(Suppl. 1):132. doi: 10.1159/000248474.

42. Takashima A., Yasuda S., Mizuno N. Determination of the action spectrum for UV-induced plasminogen activator synthesis in mouse keratinocytes in vitro. J Dermatol Sci. 1992;4:11–7. doi: 10.1016/0923-1811(92)90050-l.

43. Rotem N., Axelrod J.H., Miskin R. Induction of urokinase-type plasminogen activator by UV light in human fetal fibroblasts is mediated through a UV-induced secreted protein. Mol Cell Biol. 1987;7:622–31. doi: 10.1128/mcb.7.2.622-631.1987.

44. Kang-Rotondo C.H., Miller C.C., Morrison A.R., Pentland A.P. Enhanced keratinocyte prostaglandin synthesis after UV injury is due to increased phospholipase activity. Am J Physiol. 1993:264:396–401. doi: 10.1152/ajpcell.1993.264.2.C396.

45. Grewe M., Trefzer U., Ballhorn A., et al Analysis of the mechanism of ultraviolet (UV) B radiation-induced prostaglandin E2 synthesis by human epidermoid carcinoma cells. J Invest Dermatol. 1993;101:528–31. doi: 10.1111/1523-1747.ep12365904.

46. Wang N., Zhang L., Miles L., Hoover-Plow J. Plasminogen regulates pro-opiomelanocortin processing. J Thromb Haemost. 2004;2:785–96. doi: 10.1111/j.1538-7836.2004.00694.x.

47. Nakan T., Fujita, H., Kikuchi N., Arita H. Plasmin converts pro-form of group I phospholipase A2 into receptor binding, active forms. Biochem Biophys Res Commun. 1994;198:10–5. doi: 10.1006/bbrc.1994.1002.

48. Falcone D.J., McCaffrey T.A., Haimovitz-Friedman A., et al. Macrophage and foam cell release of matrix-bound growth factors. Role of plasminogen activation. J Biol Chem. 1993;268:11951–958.

49. Kamio N., Hashizume H., Nakao S., Matsushima K., Sugiya H. Plasmin is involved in inflammation via protease-activated receptor-1 activation in human dental pulp. Biochem Pharmacol. 2008;75:1974–80. doi: 10.1016/j.bcp.2008.02.018.

50. Horikoshi T., Eguchi H., Onodera H. The effects of tranexamic acid on the growth and melanogenesis of cultured human melanocytes. Jpn J Dermatol. 1994;104:641–46.